KERRY FARRELL: Open Payments
NPI 1891022448 · ENCINO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,342 in 44 payments from 15 companies in 2025. Trend: 2023 $562 · 2024 $2,148 · 2025 $1,342
Food & beverage: $1,342
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 10 | $416 |
| Regeneron Healthcare Solutions, Inc. | 7 | $183 |
| Lilly USA, LLC | 3 | $170 |
| ABBVIE INC. | 6 | $151 |
| Arcutis Biotherapeutics, Inc. | 4 | $81 |
| Janssen Biotech, Inc. | 2 | $54 |
| Galderma Laboratories, L.P. | 1 | $52 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 2 | $50 |
| Incyte Corporation | 2 | $42 |
| E.R. Squibb & Sons, L.L.C. | 2 | $36 |
Products named: DUPIXENT, SKYRIZI, EBGLYSS, Zoryve, TREMFYA, NEMLUVIO, TALTZ, OPZELURA.
Industry payments across CA — which companies pay providers there.
